← Back to Home

Personalized mRNA Vaccine Trial for Pediatric Brain Cancer Enrolls First Patient, With Safety and Dose to Be Assessed First

PaedNEO-VAX has moved from trial planning to enrollment, with vaccines to be made according to each patient's tumor characteristics. For hard-to-treat brain cancer, the research must first establish safety; whether it can delay progression and extend life remains to be verified.

By SURL BioNews

When a child's brain tumor recurs or stops responding to treatment, clues to new treatment approaches often must be sought in the tumor itself. Providence Therapeutics announced on November 18 that enrollment had begun in PaedNEO-VAX, a trial of a personalized mRNA cancer vaccine. The study, whose plans were announced in February this year, has now reached the enrollment of its first patient, but no post-vaccination safety or efficacy results have been released.

PTX-108, the vaccine used in the trial, is individually designed around the antigen characteristics of each patient's tumor, with the aim of guiding the immune system to recognize and attack cancer cells. The company describes the study as the world's first clinical trial of a personalized mRNA vaccine for pediatric brain cancer. This milestone marks the beginning of clinical testing for the new strategy; its efficacy remains to be established.

The study includes children and young adults with high-risk brain tumors, including recurrent or refractory high-grade glioma, medulloblastoma, ependymoma, and diffuse midline glioma. Phase 1 will assess safety and tolerability and determine the recommended dose for Phase 2. An earlier explanation from the University of Queensland stated that further evaluation of cancer progression, overall survival, and quality of life would take place in Phase 2.

The personalized process begins with whole-genome sequencing of the tumor through the ZERO2 Childhood Cancer platform, followed by bioinformatics analysis by QIMR Berghofer to help select tumor-specific vaccine targets. Under the arrangements announced by the University of Queensland in February, the vaccines will be manufactured by Southern RNA in Queensland, with approximately 10 weeks expected from enrollment to vaccine readiness. This was a manufacturing timeline estimate at the time, rather than evidence that manufacturing or vaccination had been completed for the first patient.

The trial is sponsored by the Australian and New Zealand Children's Haematology/Oncology Group, ANZCHOG, and brings together universities, research institutions, and children's hospitals. Providence's latest announcement states that the study involves eight children's hospitals in Australia and New Zealand, while the University of Queensland's February plan listed eight hospitals across five Australian states. The two announcements differ in how they describe the geographic scope of the sites, and the available information does not confirm the activation status of each hospital individually.

Background

Personalized cancer vaccines seek to turn differences in tumors into clues for immune recognition. They are intended to treat existing cancer: a patient's tumor is analyzed first, and a corresponding vaccine is then made. PaedNEO-VAX therefore tests both clinical safety and whether sequencing, analysis, and individualized manufacturing can be smoothly coordinated.

The first enrollment provides a starting point for clinical evaluation of these questions. Neither announcement has yet provided data on patients' immune responses, tumor shrinkage, or improvements in survival, nor has either disclosed the first patient's tumor type or dosing status. For hard-to-treat pediatric brain cancer, this is a treatment path that is beginning to be explored; subsequent trials must determine whether it can deliver tangible benefits.

References

  1. The Manila Times
  2. Providence Therapeutics
  3. The University of Queensland